Should you buy Bruker stock now?
Yes, the technical signal for Bruker is currently BUY. Bruker trades at $51.35 as of 8/6/2026. The overall technical signal is: Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 0.020 with falling momentum (signal: 1.066); RSI is at 40.2 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $59.75 points to 16.4% upside. This is a technical observation based on current data, not investment advice.
What is the price target for Bruker stock?
The average analyst price target for Bruker is $59.75. The current price is $51.35, which gives an upside of 16.4%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $53.78 and $65.73.
Is Bruker a dividend stock?
No, Bruker does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Bruker stock?
Bruker is rated as a stock with high risk. the annual standard deviation is 57.1%, which classifies the stock as high risk.
Is Bruker overvalued?
No, Bruker is considered undervalued based on the analyst price target (16.4% upside). Bruker has the following valuation ratios: a P/S ratio of 2.2, a P/B ratio of 3.9. The analyst price target suggests that the stock is undervalued by 16.4%.
Is Bruker overbought?
No, Bruker is not overbought. RSI is at 40.2 (neutral zone). The technical indicators show: RSI is at 40.2 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 13.9% below the 20-day average (short-term downtrend). In addition, MACD is positive, but momentum is falling.
When is the next Bruker earnings report?
The date of the next earnings report for Bruker has not been published yet. Check the company's investor calendar for updates.
Is Bruker shorted?
Yes, Bruker is shorted with 18.5% of the free float sold short. This is a very high level of short selling, which points to considerable bearish sentiment. A positive earnings report or unexpectedly good news can trigger a short squeeze with sharp price gains. Data is updated daily based on official filings with the SEC.
Are insiders buying Bruker stock?
No, insiders are not buying Bruker shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 3 sales. On a net basis, 317,820 $ worth of shares were sold. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 3,300,718 $ sold. Active sellers include Munch Mark, Mark Munch, Bures Thomas and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Bruker a good stock?
Based on our total score, Bruker is rated as a mediocre stock with a total score of 43 out of 100. The stock scores around average on value, quality and momentum – it sits near the median in our database. The score is made up of Value: 28/100, Quality: 38/100, Momentum: 62/100. In addition: analysts see 16.4% upside to the price target; technical signal: Buy. Whether Bruker is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Bruker stock?
The outlook for Bruker based on current data: the average analyst price target is $59.75 (+16.4%). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Bruker stock falling?
Bruker is falling right now. The technical indicators show: the price is 13.9% below the 20-day average; short interest is 18.5% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Bruker go?
The average analyst price target for Bruker is $59.75, which corresponds to a potential gain of 16.4% from the current price of $51.35. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Bruker fall?
We lack enough history to give a specific floor for Bruker. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Bruker do?
Bruker Corporation tjener penge på at udvikle, producere og sælge videnskabelige instrumenter samt løsninger til analyse og diagnostik. Det er især inden for biovidenskab, de er store. Virksomheden sælger deres udstyr globalt, både i USA, Europa og Asien.
De er kendt for at l... The company belongs to the Sundhed sector, more specifically the Medicinprodukter industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Bruker as an investment.
Did Bruker raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Bruker. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Bruker making money or losing money?
No, Bruker is currently not making money — the company is losing money with a negative profit margin of -0.3%, a small loss. That means the business loses money on every dollar of revenue. The operating margin, however, is positive at 6.2% — the core business makes money; the loss comes from financing costs, taxes or one-off items. For growth stocks investing in expansion this is normal — but it raises the risk if the company does not reach break-even before its capital runs out.
Can Bruker go bankrupt?
The bankruptcy risk of Bruker is rated as moderate. Altman Z2 (a model for assessing financial distress) is 1.82 — that places the company in the middle zone. The Piotroski score (financial health 0-9, higher is better) is 6 — which is average. Debt relative to equity is 224% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Bruker have a lot of debt?
Yes, Bruker has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 224%. For the sundhed sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
